TY  - GEN
AU  - Bernardo, Lorena
AU  - Solana, Jose Carlos
AU  - Sanchez Herrero, Carmen
AU  - Torres Garcia, Ana Maria
AU  - Reyes-Cruz, Eder Yaveth
AU  - Carrillo, Eugenia
AU  - Moreno, Javier
PY  - 2023
DO  - 10.3389/fimmu.2023.1285943
UR  - http://hdl.handle.net/20.500.12105/16952
AB  - Background: Immunosuppression is a major risk factor for the development of visceral leishmaniasis (VL). The number of patients receiving immunosuppressant drugs such as TNF antagonist (anti-TNF) and methotrexate (MTX) is increasing. In these...
LA  - eng
PB  - Frontiers Media
KW  - Visceral leishmaniasis
KW  - Immunosuppression
KW  - Immunosuppressants
KW  - BALB/c mice
KW  - TNF antagonist
KW  - Methotrexate
KW  - Glucantime®
KW  - Leishmania infantum
KW  - Leishmaniasis
KW  - Leishmaniasis, Visceral
KW  - Parasites
KW  - Humans
KW  - Animals
KW  - Mice
KW  - Meglumine Antimoniate
KW  - CD8-Positive T-Lymphocytes
KW  - Immunosuppressive Agents
KW  - Tumor Necrosis Factor Inhibitors
KW  - Disease Models, Animal
KW  - Immunity, Cellular
KW  - Recurrence
TI  - Immunosuppressants alter the immune response associated with Glucantime® treatment for Leishmania infantum infection in a mouse model
TY  - research article
ER  -